News stories about Impax Laboratories (NASDAQ:IPXL) have been trending positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Impax Laboratories earned a news sentiment score of 0.28 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 50.7385352274593 out of 100, indicating that recent news coverage is somewhat likely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
- SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Impax Laboratories, Inc. and Encourages Investors to Contact the Firm for Additional … (businesswire.com)
- SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Impax Laboratories, Inc. and Encourages Investors to Contact the Firm for Additional Information (finance.yahoo.com)
- $198.42 Million in Sales Expected for Impax Laboratories, Inc. (IPXL) This Quarter (americanbankingnews.com)
- Praesidium Investment Management Company Has Cut By $7.98 Million Its Progress Software (PRGS) Stake; Impax … – Hill Country Times (hillcountrytimes.com)
- SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of … – PR Newswire (press release) (prnewswire.com)
Several brokerages have commented on IPXL. Canaccord Genuity set a $19.00 price objective on Impax Laboratories and gave the company a “hold” rating in a research report on Wednesday, August 9th. Royal Bank Of Canada set a $17.00 price objective on Impax Laboratories and gave the company a “hold” rating in a research report on Thursday, August 10th. Piper Jaffray Companies set a $17.00 price target on Impax Laboratories and gave the company a “hold” rating in a report on Thursday, August 10th. Cantor Fitzgerald set a $20.00 price target on Impax Laboratories and gave the company a “buy” rating in a report on Wednesday, August 9th. Finally, Cowen set a $20.00 price target on Impax Laboratories and gave the company a “hold” rating in a report on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company’s stock. Impax Laboratories presently has a consensus rating of “Hold” and an average price target of $19.60.
Impax Laboratories (NASDAQ:IPXL) last issued its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.03. Impax Laboratories had a positive return on equity of 9.06% and a negative net margin of 56.59%. The firm had revenue of $206.40 million during the quarter, compared to the consensus estimate of $208.38 million. During the same period last year, the company earned $0.37 earnings per share. The company’s revenue was down 9.4% on a year-over-year basis. sell-side analysts anticipate that Impax Laboratories will post 0.63 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Positive Press Coverage Somewhat Likely to Impact Impax Laboratories (IPXL) Share Price” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3079020/positive-press-coverage-somewhat-likely-to-impact-impax-laboratories-ipxl-share-price.html.
Impax Laboratories Company Profile
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.